TD Cowen comments on BridgeBio Pharma following positive infigratinib data
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a buy rating and $95 price target on BridgeBio Pharma (NASDAQ: BBIO), according ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
